BACKGROUND: Repeat infection with Chlamydia trachomatis following treatment is common and increases the risk of sequelae. Despite clinical guidelines recommending rescreening within 3 months of treatment, rescreening rates remain low. We undertook a systematic review to identify studies that compared rates of rescreening for repeat chlamydial infection between patients receiving and not receiving an intervention. METHODS: We searched Medline, EMBASE, and conference Web sites from 2000 to September 2010 using variations of the terms "chlamydia" and "rescreening" and "intervention." We used meta-analysis to calculate the overall relative risk (RR) effect on rescreening rates by study design and strategy type. RESULTS: We identified 8 randomized controlled trials (RCTs) and 4 controlled observational studies, all conducted in the United States. Four RCTs assessed mailed screening kits ± reminders, with an average effect estimate of 1.30 (95% confidence interval [CI]: 1.01-1.50); 2 RCTs assessed motivational interviewing ± reminders with a summary effect of 2.15 (95% CI: 0.92-3.37); one RCT evaluated the effect of reminders with a RR of 9.67 (95% CI: 1.31-71.31), and another RCT assessed the effect of a $20 patient incentive with a RR of 1.16 (95% CI: 0.62-2.17). Three controlled observational studies assessed reminder strategies with RRs of 1.97 (95% CI: 1.76-2.21), 1.01 (95% CI: 0.66-1.55), and 1.88 (95% CI: 1.58-2.24)-a summary effect was not calculated due to significant heterogeneity; and one controlled observational study assessed the promotion of clinical guidelines with a RR of 1.35 (95% CI: 0.96-1.90). CONCLUSION: The review suggests that the use of mailed screening kits is an important strategy to increase rescreening, reminder systems are promising, and motivational interviewing is worth investigation.
BACKGROUND:Repeat infection with Chlamydia trachomatis following treatment is common and increases the risk of sequelae. Despite clinical guidelines recommending rescreening within 3 months of treatment, rescreening rates remain low. We undertook a systematic review to identify studies that compared rates of rescreening for repeat chlamydial infection between patients receiving and not receiving an intervention. METHODS: We searched Medline, EMBASE, and conference Web sites from 2000 to September 2010 using variations of the terms "chlamydia" and "rescreening" and "intervention." We used meta-analysis to calculate the overall relative risk (RR) effect on rescreening rates by study design and strategy type. RESULTS: We identified 8 randomized controlled trials (RCTs) and 4 controlled observational studies, all conducted in the United States. Four RCTs assessed mailed screening kits ± reminders, with an average effect estimate of 1.30 (95% confidence interval [CI]: 1.01-1.50); 2 RCTs assessed motivational interviewing ± reminders with a summary effect of 2.15 (95% CI: 0.92-3.37); one RCT evaluated the effect of reminders with a RR of 9.67 (95% CI: 1.31-71.31), and another RCT assessed the effect of a $20 patient incentive with a RR of 1.16 (95% CI: 0.62-2.17). Three controlled observational studies assessed reminder strategies with RRs of 1.97 (95% CI: 1.76-2.21), 1.01 (95% CI: 0.66-1.55), and 1.88 (95% CI: 1.58-2.24)-a summary effect was not calculated due to significant heterogeneity; and one controlled observational study assessed the promotion of clinical guidelines with a RR of 1.35 (95% CI: 0.96-1.90). CONCLUSION: The review suggests that the use of mailed screening kits is an important strategy to increase rescreening, reminder systems are promising, and motivational interviewing is worth investigation.
Authors: Elizabeth C Dee; Katherine K Hsu; Benjamin A Kruskal; John T Menchaca; Bob Zambarano; Noelle Cocoros; Brian Herrick; Michelle D Payne Weiss; Ellen Hafer; Diana Erani; Mark Josephson; Jessica Young; Elizabeth A Torrone; Elaine W Flagg; Michael Klompas Journal: Am J Prev Med Date: 2019-03 Impact factor: 5.043
Authors: Charlotte A Gaydos; Mathilda Barnes; Mary Jett-Goheen; Nicole Quinn; Pamela Whittle; Terry Hogan; Yu-Hsiang Hsieh Journal: Int J STD AIDS Date: 2013-07-15 Impact factor: 1.359
Authors: Jennifer Walker; Sepehr N Tabrizi; Christopher K Fairley; Marcus Y Chen; Catriona S Bradshaw; Jimmy Twin; Nicole Taylor; Basil Donovan; John M Kaldor; Kathleen McNamee; Eve Urban; Sandra Walker; Marian Currie; Hudson Birden; Francis Bowden; Jane Gunn; Marie Pirotta; Lyle Gurrin; Veerakathy Harindra; Suzanne M Garland; Jane S Hocking Journal: PLoS One Date: 2012-05-25 Impact factor: 3.240
Authors: Kirsty S Smith; Jane S Hocking; Marcus Chen; Christopher K Fairley; Anna McNulty; Phillip Read; Catriona S Bradshaw; Sepehr N Tabrizi; Handan Wand; Marion Saville; William Rawlinson; Suzanne M Garland; Basil Donovan; John M Kaldor; Rebecca Guy Journal: BMC Infect Dis Date: 2014-04-24 Impact factor: 3.090
Authors: Nicole H T M Dukers-Muijrers; Kevin A T M Theunissen; Petra T Wolffs; Gerjo Kok; Christian J P A Hoebe Journal: PLoS One Date: 2015-07-31 Impact factor: 3.240
Authors: Rebecca J Guy; Lisa Natoli; James Ward; Louise Causer; Belinda Hengel; David Whiley; Sepehr N Tabrizi; Basil Donovan; Christopher K Fairley; Steven B Badman; Annie Tangey; Handan Wand; Mark Shephard; David G Regan; David Wilson; David Anderson; John M Kaldor Journal: BMC Infect Dis Date: 2013-10-18 Impact factor: 3.090
Authors: Gill A Ten Hoor; Robert A C Ruiter; Jan E A M van Bergen; Christian J P A Hoebe; Nicole H T M Dukers-Muijrers; Gerjo Kok Journal: BMC Public Health Date: 2016-01-20 Impact factor: 3.295